<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="2679">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 14, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04432298</url>
  </required_header>
  <id_info>
    <org_study_id>FGCL-3019-098</org_study_id>
    <nct_id>NCT04432298</nct_id>
  </id_info>
  <brief_title>Study of the Efficacy and Safety of Intravenous Pamrevlumab, in Hospitalized Participants With Acute COVID-19 Disease</brief_title>
  <official_title>Randomized, Double-Blind, Placebo-Controlled Phase 2 Study of the Efficacy and Safety of Intravenous Pamrevlumab, a Monoclonal Antibody Against Connective Tissue Growth Factor (CTGF), in Hospitalized Patients With Acute COVID-19 Disease</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>FibroGen</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>FibroGen</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study evaluates the efficacy and safety of intravenous (IV) infusions of pamrevlumab&#xD;
      when compared with placebo in participants who are hospitalized with acute COVID-19 disease.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a randomized, double-blind, placebo-controlled, phase 2, proof-of-concept study to&#xD;
      evaluate the efficacy and safety of IV pamrevlumab, a monoclonal antibody, against&#xD;
      connective-tissue growth factor (CTGF), in participants hospitalized with acute COVID-19&#xD;
      disease.&#xD;
&#xD;
      All concomitant medications, including approved and non-approved treatments for COVID-19&#xD;
      (such as, hydroxychloroquine or interleukin 6 [IL-6] inhibitors), as well as supplemental&#xD;
      oxygenation needs, will be collected and recorded. In addition, the following will be&#xD;
      collected and recorded: documentation of Severe Acute Respiratory Syndrome coronavirus&#xD;
      (SARS-Cov-2) infection, documentation of any other infection(s) prior to or during&#xD;
      hospitalization, and whether or not aggressive care is withheld or withdrawn, including the&#xD;
      reason for withholding or withdrawal of care (such as a Do Not Resuscitate/Do Not Intubate&#xD;
      [DNR/DNI] order or a resource limitation).&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    The study was terminated by Sponsor due to low enrollment.&#xD;
  </why_stopped>
  <start_date type="Actual">June 20, 2020</start_date>
  <completion_date type="Actual">March 22, 2021</completion_date>
  <primary_completion_date type="Actual">March 22, 2021</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>Proof-of-concept</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Proportion of Participants Alive Who Never Received Mechanical Ventilation and/or Extracorporeal Membrane Oxygenation (ECMO)</measure>
    <time_frame>up to Day 28</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Proportion of Participants Alive Who Never Received Mechanical Ventilation and/or Extracorporeal Membrane Oxygenation (ECMO)</measure>
    <time_frame>up to Day 14</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of Participants Alive, Discharged Home, and Not on Supplemental Oxygen</measure>
    <time_frame>up to Day 28</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to Recovery as Based on a Modified 8-Point Ordinal Scale</measure>
    <time_frame>up to Day 28</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Days in Intensive Care Unit/Critical Care Unit (ICU/CCU) (Either on or off Mechanical Ventilation and/or ECMO)</measure>
    <time_frame>up to Day 28</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Days on Mechanical Ventilation and/or ECMO</measure>
    <time_frame>up to Day 28</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to Death from Any Cause</measure>
    <time_frame>up to Day 28</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes in Pressure of Arterial Oxygen to Fractional Inspired Oxygen Concentration (PaO2/FiO2) Ratio, Both as Categorical and Continuous Variables</measure>
    <time_frame>up to Day 28</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Resting Peripheral oxygen saturation (SpO2) Adjusted by FiO2</measure>
    <time_frame>up to Day 28</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in (Non-invasive) Oxygen Supplementation Requirements</measure>
    <time_frame>up to Day 28</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">22</enrollment>
  <condition>COVID-19</condition>
  <arm_group>
    <arm_group_label>Pamrevlumab</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Pamrevlumab: 35 milligrams/kilogram (mg/kg) on Days 1, 7, 14 and 28 for a total of 4 infusions over 4 weeks</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Pamrevlumab-matching placebo on Days 1, 7, 14 and 28 for a total of 4 infusions over 4 weeks</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Pamrevlumab</intervention_name>
    <description>Sterile liquid for injection</description>
    <arm_group_label>Pamrevlumab</arm_group_label>
    <other_name>FG-3019</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Sterile liquid for injection</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Confirmed SARS-CoV-2 infection&#xD;
&#xD;
          2. Respiratory compromise requiring hospitalization for COVID-19 disease as evidenced by&#xD;
             at least one (or more) of the following criteria:&#xD;
&#xD;
               -  Interstitial pneumonia on chest x-ray or high-resolution computed tomography&#xD;
                  (findings of consolidation or ground glass opacities), OR&#xD;
&#xD;
               -  Peripheral capillary oxygen saturation &lt; 94% on room air, OR&#xD;
&#xD;
               -  Requiring non-invasive supplemental oxygen (such as, nasal cannula, face mask) to&#xD;
                  maintain SpO2&#xD;
&#xD;
          3. Not requiring mechanical ventilation and/or extracorporeal membrane oxygenation (ECMO)&#xD;
             use at time of randomization&#xD;
&#xD;
          4. Not participating in another clinical trial for the treatment of COVID-19 disease&#xD;
             through Day 28&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Female participants who are pregnant or nursing&#xD;
&#xD;
          2. Participation in a clinical trial with another investigational drug for COVID-19&#xD;
             disease&#xD;
&#xD;
          3. Anticipated discharge from the hospital or transfer to another hospital or long-term&#xD;
             care facility which is not a study site within 72 hours of randomization&#xD;
&#xD;
          4. History of allergic or anaphylactic reaction to human, humanized, chimeric or murine&#xD;
             monoclonal antibodies&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>40 Years</minimum_age>
    <maximum_age>85 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Research Center</name>
      <address>
        <city>Detroit</city>
        <state>Michigan</state>
        <zip>48202</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Center</name>
      <address>
        <city>Greensboro</city>
        <state>North Carolina</state>
        <zip>27403</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Center</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19107</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Center</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19140</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>March 2021</verification_date>
  <study_first_submitted>June 12, 2020</study_first_submitted>
  <study_first_submitted_qc>June 12, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">June 16, 2020</study_first_posted>
  <last_update_submitted>March 31, 2021</last_update_submitted>
  <last_update_submitted_qc>March 31, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">April 2, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Severe Acute Respiratory Syndrome coronavirus</keyword>
  <keyword>SARS-COV-2 infection</keyword>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

